Nicholas Brumm

Nicholas Brumm is one of the principal owners and Managing Members of QVT Financial LP, the New York-based investment firm now operating as QVT Family Office. He is one of the original members of the QVT group, which began as a non-traditional proprietary trading group inside Deutsche Bank before spinning out as an independent manager. He has been with the QVT organization since its earliest days, with sources placing his tenure at the firm from roughly 2003. His primary portfolio-management focus is private equity, distressed and high-yield investing, and other special situations.

Before QVT became an independent firm, Brumm served as a Director of DB Advisors, a subsidiary of Deutsche Bank AG. He joined Deutsche Bank in 2000 as a member of the QVT group and remained there until the group's transition to an independent platform around 2004. Earlier in his career, from 1992 to 2000, he practiced law at Cravath, Swaine & Moore in New York and at Hengeler Mueller Weitzel Wirtz in Germany, working on domestic and international securities offerings, mergers and acquisitions, and bank and high-yield lending — experience that maps closely to QVT's later work in complex, structured, and litigation-driven situations.

Brumm has an unusually academic, international background, consistent with QVT's self-description as "a group of original thinkers with non-traditional backgrounds." He earned an A.B. in History and Literature, *summa cum laude*, from Harvard College (1988), and a Master's in History, *avec mention très bien*, from the University of Paris (1989). Firm materials also list a law degree from Oxford University (First Class Honours) and an LL.M. from Columbia University. At QVT his stated areas of focus include distressed investments, litigation, media, and private funds.

• Invests through QVT Financial / QVT Family Office rather than as a standalone personal angel; QVT manages the capital of its principals and a small group of private investors after refocusing around 2018.
• QVT deploys capital across five core areas: biotech & healthcare, technology, energy & shipping, financials & structured finance, and opportunistic/litigation situations.
• In biotech, the firm is explicitly active in early-stage and seed private investing — it "seeded" and remains the largest investor in Roivant Sciences, and was among the earliest and largest investors in Pharmasset and Medivation.
• In technology, QVT makes "early and majority investments in private companies," with a stated emphasis on semiconductors.
• Brumm's personal focus areas — distressed, litigation, media, and private funds — signal appetite for complex, contrarian, and hard-to-value situations rather than conventional growth-equity plays.
• The firm frames its philosophy around change as a fundamental driver of opportunity, favoring differentiated, non-consensus theses over crowded trades.